Fulgent Beats Q2 2025 EPS, Raises Guidance

Fulgent Genetics reported strong Q2 2025 results, with revenue rising 15–16% year over year to $81.8 million and adjusted (non-GAAP) earnings per share of $0.07, beating expectations of a loss. This marks the company's fourth straight quarter of outperforming analyst forecasts. Fulgent raised its full-year 2025 revenue guidance to $320 million and now anticipates a smaller adjusted loss per share than previously projected. Despite these positives, the company posted a wider GAAP net loss of $19.3 million, mainly due to a one-time impairment and higher operating expenses. Growth was fueled by laboratory services, especially in precision diagnostics, anatomic pathology, and BioPharma, while international revenues declined following the absence of a previous one-time licensing deal. Shares rose sharply in response, though the stock remains down overall for the year.